Thursday, August 4, 2011
Massachusetts researchers have created
mice with human ectopic artificial livers that were used to evaluate
human drug metabolism, drug-drug interactions and drug-induced liver injury in
a proof-of-principle study.1 Unlike animal models that are currently
under development for monitoring liver toxicity, the new mice are healthy and
immunocompetent, which might give a better picture of outcomes in humans.
T. SciBX 4(30);
Published online Aug. 4, 2011
1. Chen, A.A. et al.
Proc. Natl. Acad. Sci. USA; published online
July 11, 2011; doi:10.1073/pnas.1101791108
Contact: Sangeeta Bhatia, Massachusetts Institute of Technology, Cambridge,
Contact: Alice Chen, same affiliation as above
2. Hasegawa, M. et al.
Mol. Pharmacol.; published online May 31, 2011; doi:10.1124/mol.111.071845
3. Khetani, S.R. &
Bhatia, S.N. Nat. Biotechnol. 26, 120-126 (2008)
4. Wang, W.W. et al.
Drug Metab. Dispos. 38, 1900-1905 (2010)
COMPANIES AND INSTITUTIONS MENTIONED
Brigham and Women's Hospital, Boston, Mass.
Broad Institute of MIT and Harvard, Cambridge, Mass.
Dana-Farber Cancer Institute, Boston, Mass.
Harvard University, Cambridge, Mass.
Hepregen Corp., Medford, Mass.
Massachusetts Institute of Technology, Cambridge, Mass.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Taconic Farms Inc., Hudson, N.Y.